According to a recent LinkedIn post from Francis Medical, the company is highlighting clinical and procedural attributes of its Vanquish Water Vapor Ablation System for prostate lesion treatment. The post emphasizes that the system is designed for targeted ablation across multiple prostate zones, delivered transurethrally using standard cystoscopy and transrectal ultrasound (TRUS).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn content points to reported high patient satisfaction and low rates of urinary incontinence and erectile dysfunction, and directs readers to results from the VAPOR 2 Study as supporting data. For investors, the focus on minimally invasive therapy with potentially favorable side‑effect profiles may indicate an attempt to position Vanquish competitively against existing prostate treatment options.
By underscoring U.S. FDA clearance and encouraging review of safety information, the post suggests that Francis Medical is moving from pure development toward commercial or pre‑commercial emphasis around Vanquish. If the clinical outcomes referenced by the VAPOR 2 Study translate into broader physician adoption, the system could support revenue growth and strengthen the company’s standing within the urology and MedTech markets.